|Drifting a little, good time to add ahead of news on clinical trials progress.|
|Thanks - Keep the faith appears to be the message.|
|Read Panmure Gordon & Co's note on ALLERGY THERAPEUTICS, out this morning, by visiting hxxps://www.research-tree.com/company/GB00B02LCQ05
"We added Allergy Therapeutics to the Conviction List in Q315 and the strength of the share price performance during 2H15 saw the stock as one of our top performers. Interim results in March confirmed strong double digit constant currency revenue growth against a flat market backdrop. We expect catalysts in 2016 to include key clinical updates and continued commercial traction underpinning market share gains, so with the share price presently in the mid- 20p range we repeat..."|
|This looks much better in blue!|
|Netscientific Appoints Ian Postlethwaite as Chief Financial Officer
London, UK - 5th April 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to announce that Ian Postlethwaite has accepted the role as Chief Financial Officer. Ian will join the Company and the Board as soon as his current employer has appointed a suitable successor and allowed time for an orderly handover. A subsequent announcement detailing Ian's start date will be made in due course.
Ian Postlethwaite is currently the Finance Director and Company Secretary of Allergy Therapeutics plc, where he has held the roles since May 2002. Ian previously held senior finance and executive management positions with AFS (1997-2002), Ericsson (1994-1997) and Phillips Electronics (1989-1994). Ian is a Fellow of the Chartered Association of Certified Accountants. He graduated from Aston University in 1985 with a BSc (Hons) in Geological Sciences.
Commenting on the appointment, Sir Richard Sykes, Chairman of NetScientific, said: "I am delighted to welcome Ian to NetScientific as our new Chief Financial Officer. His wealth of experience at Board level in raising capital for listed growth companies with international operations in the healthcare sector will be a huge asset to the Company as we move forward with our new focus on digital health, diagnostics and therapeutics.
"We very much look forward to working with Ian as he becomes a pivotal member of our team. Until he commences Mark Nanovich will continue in his role as Interim CFO, and we would like to thank Mark for his continued contribution in helping to support the business during our recent period of transition."
Ian Postlethwaite commented: "I am excited to be joining NetScientific - this is a rapidly progressing group with an exciting portfolio of high-quality assets focused on dynamic new areas in healthcare. I look forward to working with the team to build value."|
|Take a look at this. Look very upbeat to me
|'Moribund' springs to mind.
With hindsight, that is perhaps too harsh...lol
(of a person) at the point of death.
"on examination she was moribund and dehydrated"
synonyms: dying, expiring, on one's deathbed, near death, near the end, at death's door, breathing one's last, fading/sinking fast, not long for this world, failing rapidly, on one's last legs, in extremis; informalwith one foot in the grave
"the patient was moribund"
antonyms: thriving, recovering
(of a thing) in terminal decline; lacking vitality or vigour.
"the moribund commercial property market"
synonyms: declining, in decline, on the decline, waning, dying, stagnating, stagnant, decaying, crumbling, atrophying, obsolescent, on its last legs; informalon the way out
"the country's moribund shipbuilding industry|
Bullish Gap Up for Allergy Therapeutics plc After Better FundamentalsDavid Hannula | March 9, 2016
The stock of Allergy Therapeutics plc (LON:AGY) gapped up by GBX 0.25 today and has GBX 37.05 target or 34.00% above today’s GBX 27.65 share price. The 6 months technical chart setup indicates low risk for the GBX 162.86 million company. The gap was reported on Mar, 9 by Barchart.com. If the GBX 37.05 price target is reached, the company will be worth GBX 55.37M more. Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 1.47% or GBX 0.4 on March 8, hitting GBX 27.65. About 26,621 shares traded hands. Allergy Therapeutics plc (LON:AGY) has risen 3.29% since August 6, 2015 and is uptrending. It has outperformed by 8.95% the S&P500.
Out of 3 analysts covering Allergy Therapeutics PLC (LON:AGY), 3 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Allergy Therapeutics PLC was the topic in 13 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Panmure Gordon maintained the stock on March 8 with “Buy” rating.
Allergy Therapeutics Plc is a United Kingdom pharmaceutical company. The company has a market cap of 162.86 million GBP. The Firm focuses on the treatment and prevention of allergy with aluminum free products. It has 294.15 P/E ratio. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.|
|The analysts Q.& A. session will be on the website later I understand.|
Below is a short TV interview with Manuel & Ian covering today's interim results.
Below is a short TV interview with Manuel & Ian covering today's interim results.
|Another solid and encouraging RNS from AGY this morning. We do appear to have a significant number of potentially pivotal announcements in the next twelve months. Steady away until the USA results which quietly slipped from quarter two this morning to later this year! or perhaps another piece of infrastructure.
Congratulations AGY. SUREFOOTED AS EVER.|
|Solid growth, otherwise not too many surprises. Next 6 months will be key in terms of the US opportunity. I don't expect any fireworks with the share price until we have positive outcomes in the ongoing trials. At some point the US upside will start being priced in but we're not there yet.|
|Well no big rise pre-interims. Not expecting any big surprises but hopefully the currency tailwinds will work in their favour|
|Salted or dry roasted?
Agy still flying under the radar but I'm sure some are grabbing when they can as stock keeps going very tight, only 1k available online this morning.
Hardman & Co issues research report on Allergy Therapeutics
Development progress: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. It has an underlying profitable and cash generative business despite its lead product being available only on a 'Named Patient' basis. However, protocols agreed with EU and US regulators are in place to get Pollinex Quattro approved as a biological. The US opportunity is enormous and only two players have short-course treatments. There is a valuation mis-match between AGY and its peers, which either have no growth or little marketing experience, which provides scope for considerable upside towards our risk-adjusted DCF valuation of 89p per share.|
|Its news on peanuts that I am particularly interested in.|
|Added a few, stock is very tight.
Interim results aren't far away, might get a mention that the pound is a lot weaker against the Euro which bodes well as I'm used to the wording currency headwinds.
It's been looking a lot better since the start of December.
|Just a change in spread really. It should get more interesting as US results approach.|
|this is why!!!!!!!
|AN INTERESTING HIKE THIS MORNING!|
|Well they are trying hard to move the share price north!|
Am I alone in scratching my head at the share price travails here?
Do we have exposure to China?
Does the weakened pound impact negatively?
Are the various trials all behind schedule?
|Nobody can say that that the company are unsure about the success of this revolutionary product.....
Tim Higenbottam, Research & Development Director of Allergy Therapeutics, said:
"We have completed recruitment in the G204 US study within schedule., We are confident that the results will build on the previous positive data for our MATAMPL studies and, combined with the commercial success of Pollinex Quattro in Europe, this will prepare the ground for entry in to the high value US market. GrassMATAMPL has the potential to become the best in class ultra-short course SCIT in the US market and we look forward to reporting headline data at the end of the first half of 2016."|